Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;8(11):e915-e923.
doi: 10.1016/S2542-5196(24)00245-6.

Effect of alternative dosing strategies of pembrolizumab and nivolumab on health-care emissions in the Netherlands: a carbon footprint analysis

Ruben Malmberg  1 , Jurrien H Loosveld  2 , Hans-Peter Schilte  3 , Alex Burdorf  4 , Roelof W F van Leeuwen  5
Affiliations
Free article

Effect of alternative dosing strategies of pembrolizumab and nivolumab on health-care emissions in the Netherlands: a carbon footprint analysis

Ruben Malmberg et al. Lancet Planet Health. 2024 Nov.
Free article

Abstract

Background: Hospitals contribute substantially to greenhouse gas emissions and face a moral obligation to prioritise emission reduction. Drugs constitute an important component of the greenhouse gas emissions of hospitals. Alternative dosing strategies (ADS) have been implemented to improve the cost-effectiveness of pembrolizumab and nivolumab. However, the impact of these ADS on greenhouse gas emissions remains unknown. Therefore, we aimed to analyse the effect of ADS implementation on the carbon emissions of treatment with pembrolizumab and nivolumab.

Methods: We used a process-based lifecycle assessment to quantify the environmental impact of pembrolizumab and nivolumab, focused on equivalent carbon dioxide emissions (CO2e). Lifecycle inventory and impact data from Erasmus University Medical Center (Rotterdam, Netherlands) were used to calculate the CO2e for pembrolizumab and nivolumab, their dosing intervals, and the impact of ADS on CO2e. The functional unit of the study was the administration of a single dose of pembrolizumab or nivolumab.

Findings: In 2022, the annual carbon emissions related to pembrolizumab and nivolumab treatment in the Erasmus University Medical Center were 445 tons of CO2e, averaging 94 kg of CO2e per dose. Pharmaceutical production was the main driver of treatment-related carbon emissions (mean 92·9% of total emissions). Applying ADS resulted in 21-26% and 9-11% CO2e reductions for pembrolizumab and nivolumab, respectively.

Interpretation: This study shows the environmental impact of pembrolizumab and nivolumab treatment and calls for further implementation of ADS for pembrolizumab, nivolumab, and other anti-PD-(L)1 monoclonal antibodies, and more sustainable pharmaceutical production processes. Our findings create environmental awareness and contribute to the promotion and understanding of health-care practices with lower carbon emissions.

Funding: None.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests RM reports speaker fees from Bristol Myers Squibb outside the submitted work. RWFvL reports research grants (all paid to their institution) from Bristol Myers Squibb and Pfizer, consulting fees from Bristol Myers Squibb, Pfizer, Merck Sharp & Dohme, Roche, Pierre Fabre, and AstraZeneca, speaker fees from AstraZeneca, and travel support from Ipsen, all outside the submitted work. All other authors declare no competing interests.

MeSH terms

LinkOut - more resources